A preclinical model of malignant peripheral nerve sheath tumor-like melanoma is characterized by infiltrating mast cells

Cancer Research

Volumn 76, Issue 2, 2016, Pages 251-263

  Hölzel, Michael ^a   Landsberg, Jennifer ^b   Glodde, Nicole ^b   Bald, Tobias ^b   Rogava, Meri ^b   Riesenberg, Stefanie ^a   Becker, Albert ^b   Jönsson, Göran ^c   Tüting, Thomas ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CD45 ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN 2; NERVE GROWTH FACTOR RECEPTOR; NEUROFILAMENT PROTEIN; NEUROMODULIN; OCTAMER TRANSCRIPTION FACTOR 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2 ALPHA; TRANSCRIPTION FACTOR ENGRAILED 1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR POU; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR TEAD1; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR WWTR1; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYSOSOME; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MAST CELL; MELANOMA; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; COHORT ANALYSIS; GENETICS; METABOLISM; MICROARRAY ANALYSIS; NERVE SHEATH TUMOR; PATHOLOGY; PERIPHERAL NERVE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COHORT STUDIES; GENE EXPRESSION; HUMANS; MAST CELLS; MELANOMA; MICE; MICROARRAY ANALYSIS; NERVE SHEATH NEOPLASMS; PERIPHERAL NERVOUS SYSTEM NEOPLASMS;

EID: 84959020089     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1090     Document Type: Article

References (50)

1. Banerjee SS, Harris M. Morphological and immunophenotypic variations in malignant melanoma. Histopathology 2000;36:387-402.
2. Cheli Y,Giuliano S, Guiliano S, Botton T, Rocchi S,Hofman V, et al.Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011; 30:2307-18.
3. Hoek KS, Goding CR. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010;23:746-59.
4. Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 2013;13:365-76.
5. Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012;490:412-6.
6. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014;507:109-13.
7. Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, et al. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012;31:2461-70.
8. Widmer DS, Hoek KS, Cheng PF, Eichhoff OM, Biedermann T, Raaijmakers MIG, et al. Hypoxia contributes to melanoma heterogeneity by triggering HIF1a-dependent phenotype switching. J Invest Dermatol 2013;133: 2436-43.
9. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, et al. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 2005;65:11493-500.
10. Yajima I, Belloir E, Bourgeois Y, Kumasaka M, Delmas V, Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genes 2006;44:34-43.
11. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 1999;22:44-52.
12. Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun 2015;6:6683.
13. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
14. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
15. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95.
16. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 2014;4:674-87.
17. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009;15:294-303.
18. Tormo D, Ferrer A, Gaffal E, Wenzel J, Basner-Tschakarjan E, Steitz J, et al. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol 2006;169:665-72.
19. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006;19:290-302.
20. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1a and MITF. Cancer Cell 2013;23:302-15.
21. Ploper D, Taelman VF, Robert L, Perez BS, Titz B, Chen H-W, et al. MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells. Proc Natl Acad Sci U S A 2015;112:E420-9.
22. Praetorius C, Grill C, Stacey SN, Metcalf AM, Gorkin DU, Robinson KC, et al. A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 2013;155:1022-33.
23. Wurst W, Auerbach AB, Joyner AL. Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum. Development 1994;120:2065-75.
24. Jaegle M, GhazviniM,Mandemakers W, PiirsooM, Driegen S, Levavasseur F, et al. The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development. Genes Dev 2003;17:1380-91.
25. King R, Busam K, Rosai J. Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor: report of 16 cases. Am J Surg Pathol 1999;23:1499-505.
26. Halova I, Draberova L, Draber P. Mast cell chemotaxis-chemoattractants and signaling pathways. Front Immunol 2012;3:119.
27. Cirenajwi H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, et al. Molecular stratification of metastatic melanoma using gene expression profiling-prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget 2015;6:12297-309.
28. Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 2009;28:2289-98.
29. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009;41:544-52.
30. Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, et al. Elucidating distinct roles for NF1 inmelanomagenesis. Cancer Discov 2013;3:338-49.
31. Handoko HY, Boyle GM, Ferguson B, Muller HK, Soyer HP, Walker GJ. Plasticity of melanoma in vivo: murine lesions resulting from Trp53, but not Cdk4 or Arf deregulation, display neural transdifferentiation. Pigment Cell Melanoma Res 2013;26:731-4.
32. Wehbe M, Soudja SM, Mas A, Chasson L, Guinamard R, de Tenbossche CP, et al. Epithelial-mesenchymal-transition-like and TGFb pathways associated with autochthonous inflammatory melanoma development in mice. PLoS One 2012;7:e49419.
33. Reed RJ, Leonard DD. Neurotropic melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol 1979;3:301-11.
34. Schadendorf D, Haas N, Worm M, Ostmeier H, Kohlmus C, Gottschalk J, et al. Amelanotic malignant melanoma presenting as malignant Schwannoma. Br J Dermatol 1993;129:609-14.
35. Su A, Dry SM, Binder SW, Said J, Shintaku P, Sarantopoulos GP. Malignant melanoma with neural differentiation: an exceptional case report and brief review of the pertinent literature. Am J Dermatopathol 2014;36:e5-9.
36. Chen JY, Hruby G, Scolyer RA, Murali R, Hong A, Fitzgerald P, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer 2008;113:2770-8.
37. Tonks ID, Nurcombe V, Paterson C, Zournazi A, Prather C, Mould AW, et al. Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues. Genes 2003;37:131-8.
38. Adameyko I, Lallemend F, Aquino JB, Pereira JA, Topilko P,Müller T, et al. Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 2009;139:366-79.
39. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013;24:466-80.
40. Staser K, Yang F-C, Clapp DW. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu Rev Pathol 2012;7:469-95.
41. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999;286:2172-6.
42. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296: 920-2.
43. SchadendorfD, Kohlmus C, Gawlik C, Suter L, Czarnetzki BM. Mast cells in melanocytic tumours. Arch Dermatol Res 1995;287:452-6.
44. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, et al. Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003;39:666-74.
45. Jeong H-J, Oh H-A, Nam S-Y, Han N-R, Kim Y-S, Kim J-H, et al. The critical role of mast cell-derived hypoxia-inducible factor-1a in human and mice melanoma growth. Int J Cancer 2013;132:2492-501.
46. Bønnelykke-Behrndtz ML, Steiniche T, Damsgaard TE, Georgsen JB, Danielsen A, Bastholt L, et al. MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. Melanoma Res 2015;25:113-8
47. Kemper K, de Goeje PL, Peeper DS, van Amerongen R. Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res 2014;74:5937-41.
48. Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov 2014;4:816-27.
49. Menon DR, Wels C, Bonyadi Rad E, Joshi S, Knausz H, Lade-Keller J, et al. TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma. Pigment Cell Melanoma Res 2013;26:912-6.
50. Tüting T. T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. Pigment Cell Melanoma Res 2013;26:441-56.